Evidence map›Paper›PMID 32133960›Full record

ArticleCombinatorial chemistry & high throughput screening2020

Network Pharmacology-based Investigation of the Underlying Mechanism of Panax notoginseng Treatment of Diabetic Retinopathy.

Chunli Piao, Zheyu Sun, De Jin, Han Wang, Xuemin Wu, Naiwen Zhang, Fengmei Lian, Xiaolin Tong

Open access · hybridAbstract read
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Effect and mechanism of Sanqi () in treating periodontitis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  4. Network Pharmacology Study on the Mechanisms ofApplied bionics and biomechanics · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chunli PiaoShenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen, Guangdong 51800, China.
Zheyu SunShenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen, Guangdong 51800, China.
De JinGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100000, China.
Han WangShenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen, Guangdong 51800, China.
Xuemin WuShenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen, Guangdong 51800, China.
Naiwen ZhangShenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen, Guangdong 51800, China.
Fengmei LianGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100000, China.
Xiaolin TongGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100000, China.
Guangzhou University of Chinese Medicine · CNGuang’anmen Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPanax notoginseng, a Chinese herbal medicine, has been widely used to treat vascular diseases. Diabetic retinopathy (DR) is one of the complications of diabetic microangiopathy. According to recent studies, the application of Panax notoginseng extract and related Chinese patent medicine preparations can significantly improve DR. However, the pharmacological mechanisms remain unclear. Therefore, the purpose of this study was to decipher the potential mechanism of Panax notoginseng treatment of DR using network pharmacology.

methodsWe evaluated and screened the active compounds of Panax notoginseng using the Traditional Chinese Medicine Systems Pharmacology database and collected potential targets of the compounds by target fishing. A multi-source database was also used to organize targets of DR. The potential targets as the treatment of DR with Panax notoginseng were then obtained by matching the compound targets with the DR targets. Using protein-protein interaction networks and topological analysis, interactions between potential targets were identified. In addition, we also performed gene ontology-biological process and pathway enrichment analysis for the potential targets by using the Biological Information Annotation Database.

resultsEight active ingredients of Panax notoginseng and 31 potential targets for the treatment of DR were identified. The screening and enrichment analysis revealed that the treatment of DR using Panax notoginseng primarily involved 28 biological processes and 10 related pathways. Further analyses indicated that angiogenesis, inflammatory reactions, and apoptosis may be the main processes involved in the treatment of DR with Panax notoginseng. In addition, we determined that the mechanism of intervention of Panax notoginseng in treating DR may involve five core targets, VEGFA, MMP-9, MMP-2, FGF2, and COX-2.

conclusionPanax notoginseng may treat diabetic retinopathy through the mechanism of network pharmacological analysis. The underlying molecular mechanisms were closely related to the intervention of angiogenesis, inflammation, and apoptosis with VEGFA, MMP-9, MMP-2, FGF2, and COX-2 being possible targets.

Indexed as

Databases, FactualDiabetic RetinopathyDrugs, Chinese HerbalHumansMedicine, Chinese TraditionalModels, MolecularMolecular ConformationPanax notoginsengDrugs, Chinese HerbalPanax notoginseng extractdiabetic retinopathymolecular mechanismnetwork pharmacologyPanax notoginsengtreatmentvascular disease.

Identifiers

PMID32133960
PMCPMC7497535
OpenAlexW3009602298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.